Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
Inscription Capital LLC Acquires 3,827 Shares of Charles River Laboratories International, Inc. $CRL
04:45am, Wednesday, 21'st Jan 2026
Inscription Capital LLC increased its holdings in Charles River Laboratories International, Inc. (NYSE: CRL) by 185.0% in the undefined quarter, according to the company in its most recent filing with
NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy
01:01pm, Thursday, 15'th Jan 2026
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:55pm, Tuesday, 13'th Jan 2026
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Charles River to buy Cambodia-based monkey supplier for $510 million
05:19pm, Monday, 12'th Jan 2026
Charles River Laboratories said on Monday it would buy one of its major suppliers of non-human primates for about $510 million as the contract research firm seeks greater control over procurement of t
Charles River Laboratories Provides Business Updates
04:30pm, Monday, 12'th Jan 2026
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Business Updates.
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan
08:00am, Thursday, 08'th Jan 2026
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan.
SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to
What Makes Charles River (CRL) a New Buy Stock
01:00pm, Tuesday, 06'th Jan 2026
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue?
10:16am, Tuesday, 06'th Jan 2026
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner Reed Kathrein Scrutinizing Alleged Missta
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO, Jan. 3, 2026 /PRNewswire/ -- Natio
SAN FRANCISCO, Jan. 02, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
11:26am, Friday, 02'nd Jan 2026
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
